

Jean-Claude Scimeca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8987730/publications.pdf>

Version: 2024-02-01

42
papers

1,792
citations

257101

24
h-index

276539

41
g-index

44
all docs

44
docs citations

44
times ranked

2122
citing authors

#	ARTICLE	IF	CITATIONS
1	Relationship between the oxidative status and the tumor growth in transplanted triple-negative 4T1 breast tumor mice after oral administration of rhenium(I)-diselenoether. <i>Journal of Trace Elements in Medicine and Biology</i> , 2022, 71, 126931.	1.5	3
2	Monitoring of in-vitro ultrasonic stimulation of cells by numerical modeling. <i>Ultrasonics</i> , 2022, 124, 106714.	2.1	1
3	Nano-engineered biomaterials: Safety matters and toxicity evaluation. <i>Materials Today Advances</i> , 2022, 15, 100260.	2.5	14
4	Proteomic analysis identified LBP and CD14 as key proteins in blood/biphasic calcium phosphate microparticle interactions. <i>Acta Biomaterialia</i> , 2021, 127, 298-312.	4.1	3
5	Double-edged sword: Therapeutic efficacy versus toxicity evaluations of doped titanium implants. <i>Drug Discovery Today</i> , 2021, 26, 2734-2742.	3.2	28
6	Fibrin as a Multipurpose Physiological Platform for Bone Tissue Engineering and Targeted Delivery of Bioactive Compounds. <i>Pharmaceutics</i> , 2019, 11, 556.	2.0	42
7	Gallium enhances reconstructive properties of a calcium phosphate bone biomaterial. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2018, 12, e854-e866.	1.3	20
8	Design and properties of a novel radiopaque injectable apatitic calcium phosphate cement, suitable for image-guided implantation. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2018, 106, 2786-2795.	1.6	11
9	Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2018, 19, 148.	1.8	28
10	The multiple therapeutic applications of miRNAs for bone regenerative medicine. <i>Drug Discovery Today</i> , 2017, 22, 1084-1091.	3.2	11
11	Calcium supplementation decreases BCP-induced inflammatory processes in blood cells through the NLRP3 inflammasome down-regulation. <i>Acta Biomaterialia</i> , 2017, 57, 462-471.	4.1	5
12	Determination of extracellular matrix collagen fibril architectures and pathological remodeling by polarization dependent second harmonic microscopy. <i>Scientific Reports</i> , 2017, 7, 12197.	1.6	43
13	Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases. <i>Biochemical Pharmacology</i> , 2016, 116, 11-21.	2.0	14
14	Therapeutic strategies for treating osteolytic bone metastases. <i>Drug Discovery Today</i> , 2014, 19, 1419-1426.	3.2	43
15	Adaptive Immune Response Inhibits Ectopic Mature Bone Formation Induced by BMSCs/BCP/Plasma Composite in Immune-Competent Mice. <i>Tissue Engineering - Part A</i> , 2014, 20, 2950-2962.	1.6	24
16	Gallium as a potential candidate for treatment of osteoporosis. <i>Drug Discovery Today</i> , 2012, 17, 1127-1132.	3.2	43
17	Monocytes differentiation upon treatment with a peptide corresponding to the C-terminus of activated T cell-expressed Tirc7 protein. <i>Journal of Cellular Physiology</i> , 2012, 227, 3088-3098.	2.0	0
18	Molecular effects of gallium on osteoclastic differentiation of mouse and human monocytes. <i>Biochemical Pharmacology</i> , 2012, 83, 671-679.	2.0	34

#	ARTICLE	IF	CITATIONS
19	Fate of Bone Marrow Stromal Cells in a Syngenic Model of Bone Formation. Tissue Engineering - Part A, 2011, 17, 2267-2278.	1.6	29
20	Gallium modulates osteoclastic bone resorption <i>in vitro</i> without affecting osteoblasts. British Journal of Pharmacology, 2010, 159, 1681-1692.	2.7	69
21	Biphasic Calcium Phosphate Microparticles for Bone Formation: Benefits of Combination with Blood Clot. Tissue Engineering - Part A, 2010, 16, 3495-3505.	1.6	39
22	Osteoclastic differentiation of mouse and human monocytes in a plasma clot/biphasic calcium phosphate microparticles composite. , 2010, 20, 379-392.		24
23	Poly(adp-ribose) Polymerase-1 Regulates Tracp Gene Promoter Activity During RANKL-Induced Osteoclastogenesis. Journal of Bone and Mineral Research, 2008, 23, 564-571.	3.1	18
24	Cloning and Use of a Coral 36B4 Gene to Study the Differential Expression of Coral Genes Between Light and Dark Conditions. Marine Biotechnology, 2008, 10, 653-663.	1.1	28
25	Differential Binding of Poly(ADP-Ribose) Polymerase-1 and JunD/Fra2 Accounts for RANKL-Induced Tcigr1 Gene Expression During Osteoclastogenesis. Journal of Bone and Mineral Research, 2007, 22, 975-983.	3.1	25
26	Ectopic bone formation using an injectable biphasic calcium phosphate/Si-HPMC hydrogel composite loaded with undifferentiated bone marrow stromal cells. Biomaterials, 2006, 27, 3256-3264.	5.7	109
27	RANKL Treatment Releases the Negative Regulation of the Poly(ADP-Ribose) Polymerase-1 on Tcigr1 Gene Expression During Osteoclastogenesis. Journal of Bone and Mineral Research, 2006, 21, 1757-1769.	3.1	24
28	Molecular cloning and localization of a PMCA P-type calcium ATPase from the coral Stylophora pistillata. Biochimica Et Biophysica Acta - Biomembranes, 2004, 1663, 117-126.	1.4	158
29	Novel mutations in theTCIRG1gene encoding the $\alpha 3$ subunit of the vacuolar proton pump in patients affected by infantile malignant osteopetrosis. Human Mutation, 2003, 21, 151-157.	1.1	47
30	Family of SRY/Sox proteins is involved in the regulation of the mouseMsh4 (MutS homolog 4) gene expression. Molecular Reproduction and Development, 2001, 60, 172-180.	1.0	8
31	The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. Bone, 2000, 26, 207-213.	1.4	193
32	Cloning and Recombinant Expression of a Novel Mouse-secreted Phospholipase A2. Journal of Biological Chemistry, 1999, 274, 19152-19160.	1.6	110
33	Structure, chromosome localization, and tissue distribution of the mouse twik K ⁺ channel gene. FEBS Letters, 1998, 425, 310-316.	1.3	33
34	Essential role of calcium in the regulation of MAP kinase phosphatase-1 expression. Oncogene, 1997, 15, 717-725.	2.6	58
35	Regulation of the MAP kinase cascade in PC12 cells: B-Raf activates MEK-1 (MAP kinase or ERK kinase) and is inhibited by cAMP. FEBS Letters, 1995, 357, 290-296.	1.3	78
36	Co-regulation of the mitogen-activated protein kinase, extracellular signal-regulated kinase 1, and the 90-kDa ribosomal S6 kinase in PC12 cells. Distinct effects of the neurotrophic factor, nerve growth factor, and the mitogenic factor, epidermal growth factor. Journal of Biological Chemistry, 1993, 268, 9803-10.	1.6	188

#	ARTICLE	IF	CITATIONS
37	Insulin and orthovanadate stimulate multiple phosphotyrosine-containing serine kinases. <i>Molecular and Cellular Biochemistry</i> , 1992, 109, 139-147.	1.4	7
38	Nerve growth factor-induced phosphorylation cascade in PC12 pheochromocytoma cells. Association of S6 kinase II with the microtubule-associated protein kinase, ERK1. <i>Journal of Biological Chemistry</i> , 1992, 267, 17369-74.	1.6	43
39	Tyrosine and threonine phosphorylation of an immunoaffinity-purified 44-kDa MAP kinase. <i>Biochemistry</i> , 1991, 30, 9313-9319.	1.2	30
40	Phenylarsine oxide stimulates a cytosolic tyrosine kinase activity and glucose transport in mouse fibroblasts. <i>Experimental Cell Research</i> , 1991, 197, 300-306.	1.2	18
41	Insulin binding to its receptor induces a conformational change in the receptor C-terminus. <i>Biochemistry</i> , 1990, 29, 4634-4641.	1.2	60
42	Antiphosphotyrosine antibodies modulate insulin. <i>Cellular Signalling</i> , 1989, 1, 195-204.	1.7	20